Friedman Kaplan advised PAVmed Inc. and its majority-owned subsidiary Lucid Diagnostics Inc. on the public offering. Lucid Diagnostics Inc. (Nasdaq: LUCD), a commercial-stage, cancer prevention medical diagnostics…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
